formerly of Eli Lilly and Company
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis
Article first published online: 2 DEC 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 6, pages 1337–1341, December 2013
How to Cite
Zhu, B., Edson-Heredia, E., Cameron, G.S., Shen, W., Erickson, J., Shrom, D., Wang, P., Banerjee, S. and Gordon, K.B. (2013), Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 169: 1337–1341. doi: 10.1111/bjd.12610
Funding sources Eli Lilly and Company.
Conflicts of interest B.Z., E.E.-H., G.S.C., W.S, J.E., D.S., P.W., and S.B. are all full-time employees of, and own stock in, Eli Lilly and Company. K.B.G. has received research support from Eli Lilly and Company, Amgen, Janssen Pharmaceuticals, Merck and Celgene Corporation, and honoraria from Eli Lilly and Company, Amgen, Pfizer, Janssen, Novartis, AbbVie and Celgene Corporation.
The primary results of this phase II study have previously been published (Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190–9).
- Issue published online: 2 DEC 2013
- Article first published online: 2 DEC 2013
- Accepted manuscript online: 6 SEP 2013 02:14AM EST
- Manuscript Accepted: 28 AUG 2013
- Jiaying Guo of inVentiv Health Clinical
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.